| February 3, 2010 |
|
The Accordion – Pill Carbidopa/Levodopa for the treatment of Parkinson's disease symptoms. Phase IIA was conducted in two leading Israeli medical centers, in 12 early stages PD patients. The objective was to evaluate the pharmacokinetic profiles, during the day, of AP-CD/LD 50/250mg, taken BID, in a crossover fashion with four-times a-day 25/125mg immediate release CD/LD (Dopicar® Teva Pharmaceuticals), each taken for 7 days. According to Intec's clinical advisors in the field of Parkinson’s disease, the steady-state profile of the Levodopa plasma levels which was achieved in Parkinson's disease patients, treated with the Accordion Pills, is unprecedented, compared to all currently available oral Levodopa formulations. |